About ACS Biomed
ACS Produzioni Biomed S.r.l. is an Italian life sciences company developing differentiated prescription pharmaceutical programs and innovative medical devices. Headquartered in Udine, Italy, the company operates across two strategic divisions.
Our Mission
Transforming scientific research into accessible therapies for patients worldwide. We achieve this by developing differentiated pharmaceutical programs with a solid intellectual property foundation, structured for international regulatory success and strategic global partnerships.
Every product we develop originates from a real, unmet clinical need and is built to deliver lasting market value. We believe that innovation must be practical, scalable, and ultimately beneficial to the patients who need it most.
Vision 2030
To become a recognized reference point in topical antiviral and immunomodulatory innovation, with an IP-protected and scalable portfolio designed for global commercialization.
By 2030, we aim to have at least one pharmaceutical product approved by EMA or FDA, a network of distribution partners in 20+ countries, and a pipeline of new molecules that continues to generate value for our partners and shareholders.
Organizational Structure
Our lean structure enables agile decision-making while maintaining the rigor required for pharmaceutical development and regulatory compliance.
Marketing
Commercial strategy, consumer product launch, go-to-market execution, and partner relationship management for global distribution.
Regulatory Affairs
EMA/FDA compliance, IP strategy and patent portfolio, product registrations (CPNP, UK.GOV), and international regulatory submissions.
R&D / Development
Pipeline development, CRO coordination (PPD partnership), clinical trial oversight, formulation science, and product innovation.
Board Members
Experienced professionals with deep expertise in pharmaceutical development and the medical sector.
Entrepreneur and business strategist in the Healthcare, Pharma and Medical Devices sector. Building direct access between innovation and C-level decision-makers at pharmaceutical multinationals, transforming complex opportunities into strategic partnerships, licensing and growth operations. Founder of Pharmaconnect and CEO of ACS Produzioni Biomed, a company developed from startup to structured enterprise with full P&L responsibility and international presence. Operating at the decision-making level of the industry, with an active network of global VPs, Directors and C-levels and a track record of growth, international expansion and high-value negotiations.
Marco Crozzoletto is an entrepreneur with over 25 years of experience in the medical and biomedical sector, with a focus on research, development and commercialization of innovative technologies. Since the 1990s he has worked on finding advanced therapeutic solutions, collaborating with research centers, scientific institutions and international companies in Europe, United States, Russia and Asia. Founder and leader of ZeroTime Medicals, he has built over time a high-level international network, contributing to the development and distribution of medical devices, oncological technologies and highly innovative products. His work focuses on the integration between scientific research, industrial application and market access, with the aim of concretely improving quality of life through innovation.
Our Team
We are a team of 10 dedicated professionals working to advance all company activities and bring innovative solutions to patients worldwide.
"I founded ACS Biomed to bring innovative therapies to market in areas that have been neglected for too long. Our strength lies in combining scientific rigor with entrepreneurial vision."
Our Philosophy
At ACS Biomed, we believe that scientific innovation must be grounded in practical applicability. Our approach combines rigorous research with commercial pragmatism, ensuring that every product we develop has a clear path to market and genuine clinical utility. We prioritize partnerships over pure independence, recognizing that global reach requires collaborative relationships with established pharmaceutical and distribution partners. This philosophy guides our business model: develop differentiated assets to the point of proven clinical value, then partner for scale.
Our Therapeutic Pillars
Three focused areas where we can make a meaningful difference for patients with unmet medical needs.
Antiviral Dermatology
Innovative topical solutions for recurrent viral skin infections.
Ophthalmic Immunomodulation
Targeted treatments for autoimmune eye conditions.
Nephrology MedTech
Portable medical devices to improve quality of life for patients.
CRO Partnership
Our Phase IIb/III clinical research program is conducted in partnership with PPD, the clinical research business of Thermo Fisher Scientific — one of the world's leading CROs. Study reference: BC147404-01, initiated November 2025.